Pediatric patients hospitalized with myocarditis: a multi-institutional analysis
Related Experiment Videos
Darren Klugman1, John T Berger, Craig A Sable
1Department of Pediatrics, The George Washington University School of Medicine, Critical Care Medicine and Cardiology, Children's National Medical Center, Washington, DC 20037, USA. dklugman@cnmc.org
Insights
Pediatric myocarditis patients show varied outcomes and resource use. Intravenous immunoglobulin (IVIG) did not improve survival, even in critically ill children with this heart condition.
Area of Science:
- Pediatric Cardiology
- Critical Care Medicine
- Health Services Research
Background:
- Myocarditis is a significant cause of heart dysfunction in children.
- Understanding factors influencing outcomes in pediatric myocarditis is crucial for improving patient care.
Purpose of the Study:
- To identify patient, institutional, and utilization characteristics linked to outcomes in hospitalized pediatric myocarditis cases.
- To assess the impact of specific treatments, like IVIG, on survival rates.
Main Methods:
- A nonconcurrent cohort study analyzed pediatric discharges from 35 academic children's hospitals.
- Data included patient demographics, diagnoses (myocarditis), treatments, and outcomes from 2005-2005.
- Statistical analysis examined variables associated with survival.
Main Results:
- Of 427,615 discharges, 216 (0.05%) had myocarditis.
- Common causes were idiopathic (82%), with significant resource utilization including IVIG (49.1%), mechanical ventilation (25%), and ECMO (7%).
- Overall survival was 92%; IVIG use did not impact survival (P=0.67), and higher illness severity predicted mortality.
Conclusions:
- Pediatric myocarditis patients exhibit diverse presentations and outcomes, consuming substantial resources.
- Predicting illness severity or survival based on specific characteristics proved challenging.
- IVIG did not confer a survival advantage in this pediatric myocarditis cohort, even in severe cases.
Abstract:
The objective of this study was to identify the patient, institutional, and utilization characteristics associated with outcome in hospitalized pediatric patients with myocarditis. This was a nonconcurrent cohort study of all consecutive pediatric discharges from the 35 academic children's hospitals that are members of the Pediatric Health Information System (PHIS): patients from birth through age 21 years discharged from participating hospitals between January 1, 2005, and December 31, 2005. Patient-level, institution-level, and utilization variables were examined. A total of 427,615 patients were discharged, and 216 (0.05%) were diagnosed with myocarditis. Common etiologies were idiopathic (82%), related to other diseases (6%), and bacterial or viral (3%). Myocarditis patients required considerable support including intravenous immunoglobulin (IVIG; 49.1%), milrinone (45%), epinephrine (35%), mechanical ventilation (25%), extracorporeal membrane oxygenation (7%), and cardiac transplantation (5%). Even in patients with extreme illness scores, IVIG use did not impact survival (P = 0.67). Overall survival of myocarditis patients was 92%. Myocarditis patients who died presented with a higher severity of illness and required frequent use of extracorporeal membrane oxygenation and other ICU therapies. In conclusion, pediatric patients with myocarditis have considerable variability in their presentations and outcomes, use more resources, and die more often than children with other diagnoses. Attempts at using characteristics that uniformly predict illness severity or survival were not successful. Despite increased use in the sickest patients, IVIG conferred no survival advantage.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis IV: Nursing Management
Myocarditis I: Introduction
Pericarditis III: Medical Management
Endocarditis III: Medical Management